Chinese medicine composition orally taken for curing bronchiolectasis

Abstract

The invention discloses a TCM compound for treating bronchiectasis through oral administration, which is characterized in that: the invention is prepared by the raw materials according to the following weight proportion: 10g of agrimony, eclipta prostrate 10g, 10g of radix rehmanniae, 10g of donkey hide gelatin, 10g of tatarian aster root, 10g of oriental waterplantain rhizome, 6g of baikal skullcap root, 10g of radix pseudostell, 10g of radix adenophorae, 10g of lily, 10g of drug of solomonseal, 10g of apricot kernel, 10g of stemona root, 10g of biota orientalis, 10g of cortex mori, 10g of cortex lycii radicis, 10g of common anemarrhena, 6g of cortex moutan, and 6g of fritillary bulb powder. The medicines are decocted with water, and the obtained decoction is taken with the fritillary bulb powder, one dose per day, three times a day. One continuous month is a period of treatment. The invention can nourish yin and remove fever, check exuberance of yang and stop bleeding, and has particular good effect on yin-deficiency-and-fire-hyperactivity type of bronchiectasis. Through clinical verification, the effective rate reaches 96.9 percent, and the clinical cure rate is 87.6 percent.

Description

technical field [0001] The invention relates to a traditional Chinese medicine composition for oral administration for treating bronchiectasis, which belongs to the field of traditional Chinese medicines. Background technique [0002] Bronchiectasis is a disease caused by damage to the bronchial wall resulting in dilation of the lumen. It can be complicated by a history of measles, whooping cough, post-influenza pneumonia or multiple episodes of pneumonia, tuberculosis fibrosis lesions or endobronchial tuberculosis, and lung dilatation. It is more common in children and young adults, and is characterized by chronic cough, expectoration of a large amount of purulent sputum, and recurrent hemoptysis. The disease belongs to the category of "hemoptysis", "cough" and "lung abscess" in traditional Chinese medicine. [0003] Most patients with bronchiectasis have onset in childhood and adolescence, and they are chronic and multiple secondary. Therefore, timely treatment is requir...

AI Technical Summary

Problems solved by technology

The current clinical treatment for bronchiectasis is mainly anti-inflammatory, phlegm-reducing, asthma-relieving, or surgical resection, the effect is not ideal